BDX

BD, legally Becton, Dickinson and Company, is a multinational medical technology company based in Franklin Lakes, New Jersey. It trades on the New York Stock Exchange under the ticker symbol BDX and is a member of several major indices. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson as a needle manufacturer, the company evolved into a global supplier of medical devices, diagnostics, and laboratory equipment.

BD develops and sells products used in hospitals, clinics, and laboratories worldwide. Core offerings include needle and syringe systems, safety-engineered devices to prevent needlestick injuries, blood collection and diagnostic systems, infusion therapy products, and laboratory instruments. The company maintains two primary business segments: Medical, which covers devices and systems used in patient care and procedure settings; and Life Sciences, which serves bioscience research and pharmaceutical manufacturing.

Through strategic acquisitions, BD expanded its portfolio and geographic reach. In 2015, it completed the acquisition of CareFusion for about $12.2 billion, adding infection-control and operating room products. In 2017, BD completed the acquisition of Bard Medical (C. R. Bard) for approximately $24 billion, broadening vascular access and interventional products.

BD operates globally with manufacturing, distribution, and research and development facilities in multiple regions. As a long-standing supplier to healthcare systems, BD emphasizes safety, quality, and regulatory compliance in its products and operations.